Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial Journal Article
| Authors: | Tolaney, S. M.; Tarantino, P.; Graham, N.; Tayob, N.; Parè€, L.; Villacampa, G.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M. J.; Shapira, I.; Wolff, A. C.; Carey, L. A.; Barroso-Sousa, R, ; Villagrasa, P.; DeMeo, M.; DiLullo, M.; Gomez Tejeda Zanudo, J.; Weiss, J.; Wagle, N.; Partridge, A. H.; Waks, A. G.; Hudis, C. A.; Krop, I. E.; Burstein, H. J.; Prat, A.; Winer, E. P. |
| Article Title: | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial |
| Journal Title: | Lancet Oncology |
| Volume: | 24 |
| Issue: | 3 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2023-03-01 |
| Start Page: | 273 |
| End Page: | 285 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(23)00051-7 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 36858723 |
| DOI/URL: | |
| Notes: | Accession Number: 162110829 -- Entry Date: In Process -- Revision Date: 20230301 -- Publication Type: Article -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 100957246. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work